Cryoballoon ablation for atrial fibrillation in patients with heart failure with mildly reduced and preserved ejection fraction. (3rd November 2022)

• Record Type: Journal Article
• Authors: Chen, Chaofeng; Cheng, Kuan; Gao, Xiaofei; Zou, Tian; Pang, Yang; Ling, Yunlong; Xu, Ye; Xu, Yizhou; Chen, Qingxing; Zhu, Wenqing; Ge, Junbo
• Is Part Of: ESC heart failure. Volume 10:Number 1(2023)
• Page Start: 518
• Page End: 531
• Publication Date: 2022-11-03
• Subjects: Atrial fibrillation -- Cryoballoon ablation -- Heart failure with preserved ejection fraction -- Heart failure with mildly reduced ejection fraction -- Safety and effectiveness; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.14212
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Limited data are available on the outcomes of cryoballoon ablation (CBA)‐based pulmonary vein isolation (PVI) for atrial fibrillation (AF) in patients with heart failure (HF) with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF). The present study aimed to evaluate the safety and effectiveness of CBA in such patients. Methods and results: Consecutive patients with AF referred for CBA‐based PVI from two highly experienced electrophysiology centres were included in this retrospective study. Of 651 patients undergoing CBA, 471 cases were divided into four groups: No HF ( n = 255), HFpEF ( n = 101), HFmrEF ( n = 78), and HF with reduced ejection fraction ( n = 37). Similar early recurrence of atrial arrhythmia was found among groups (16.2% vs. 15.4% vs. 14.9% vs. 12.2%, P = 0.798), and no significant difference of long‐term sinus rhythm (SR) maintenance was identified among the HFmrEF, HFpEF, and No HF groups (71.8% vs. 75.2% vs. 79.6%, P = 0.334). CBA is safe for patients with HFmrEF and HFpEF with similar complications compared with the No HF group (3.8% vs. 4.0% vs. 3.1%, P = 0.814). The reassessment of cardiac function after CBA showed that patients with HF indicated beneficial outcomes. Left atrial diameter (LAD) and left ventricular ejection fraction were significantly improved in the HFmrEF group. There were 41.6% of patients in the HFpEF group who were completely relieved from HF. LAD and New York Heart Association (NYHA) were associated with recurrence in the HFpEF and HFmrEF groups, and the maintenance of SR was an independent predictor of NYHA improvement for all HF groups. Conclusions: Patients with HFmrEF and HFpEF could benefit from CBA with high SR maintenance and significant HF improvement.